T. spiralis causes trichinellosis, which is usually transmitted to humans or other animals through the consumption of infected meat. The epitope of the 18H1 antibody contains the tri-antennary and tetra-antennary N-glycans of tyvelose, which are unique structures to T. spiralis. 18H1 binds to tyvelose (3,6-dideoxy-D-arabinohexose) on secreted glycoproteins and surface glycoproteins. The antigens carrying tyvelose are called TSL-1, which are produced in the needle cell granules in the needle bodies of the larvae and induce a strong antibody response in parasitic animals. TSL-1 antigens are modulators of the immune system and display high immunogenicity due to hydrophobic oligosaccharide chains with repeated tyvelose and fucose.
CD BioGlyco uses animal models known to be infected with T. spiralis or artificially cultured cells to produce anti-T. spiralis 18H1 antibodies through hybridoma technology and phage display technology respectively, and incubate them. We separate the cultured parasites from the culture fluid or tissue and extract the antigenic substances through cell disruption, sonication, or other methods.
CD BioGlyco uses different techniques (such as centrifugation, electrophoresis, and chromatography) to purify the extracted antigens to remove impurities and other non-target components.
CD BioGlyco performs characterization of the produced antigens, including immunogenicity assessment, immunological testing, and characterization of the antigens.
CD BioGlyco has established a powerful Carbohydrate-based Adjuvant Development platform, and we provide vaccine formulation development services based on the T. spiralis antigen. We select appropriate adjuvants, vectors, or expression systems while optimizing the combination and concentration of the antigen to achieve the best immune response and protective effect. We also provide immunological evaluation services to evaluate the immunogenicity and protective efficacy of candidate vaccines through experiments such as animal model immunity tests, antibody response analysis, and cellular immunological assays.
Fig.1 T. spiralisantigen production and vaccine formulation development services. (CD BioGlyco)
CD BioGlyco is the world's top biotechnology service company and has a powerful Glyco™ Vaccine Development Platform. We constantly pursue technological innovation and process improvement to provide better quality T. spiralis antigen production and vaccine development services. Please feel free to contact us if you would like to inquire about details.
References
